Table 3.

Association between long-term exposure to statins (at least 5 years) and the risk of MPN based on the subgroups

SubgroupCases exposed/unexposed, n/nControls exposed/unexposed, n/nOR (95% CI)aOR (95% CI)
Age group, y     
<60 46/825 189/4386 1.33 (0.94-1.88) 0.80 (0.52-1.25) 
60-75 330/1089 1772/5546 0.94 (0.82-1.08) 0.77 (0.65-0.91) 
>75 282/570 1662/2759 0.79 (0.67-0.93) 0.65 (0.54-0.78) 
Sex     
Male 300/1228 1882/6146 0.76 (0.66-0.88) 0.57 (0.47-0.68) 
Female 358/1256 1741/6545 1.06 (0.92-1.22) 0.88 (0.75-1.04) 
Disease subtype     
PV 236/829 1270/4350 0.93 (0.79-1.11) 0.73 (0.59-0.89) 
ET 215/876 1 130/4520 0.98 (0.82-1.17) 0.89 (0.72-1.10) 
MF 102/366 600/1790 0.83 (0.64-1.07) 0.60 (0.44-0.82) 
MPN-U 105/413 623/2031 0.78 (0.60-0.99) 0.52 (0.39-0.71) 
No diabetes 494/2404 2544/12 291 0.95 (0.84-1.06) 0.70 (0.63-0.82) 
No AD 581/2297 3250/11 741 0.88 (0.79-0.98) 0.69 (0.60-0.78) 
SubgroupCases exposed/unexposed, n/nControls exposed/unexposed, n/nOR (95% CI)aOR (95% CI)
Age group, y     
<60 46/825 189/4386 1.33 (0.94-1.88) 0.80 (0.52-1.25) 
60-75 330/1089 1772/5546 0.94 (0.82-1.08) 0.77 (0.65-0.91) 
>75 282/570 1662/2759 0.79 (0.67-0.93) 0.65 (0.54-0.78) 
Sex     
Male 300/1228 1882/6146 0.76 (0.66-0.88) 0.57 (0.47-0.68) 
Female 358/1256 1741/6545 1.06 (0.92-1.22) 0.88 (0.75-1.04) 
Disease subtype     
PV 236/829 1270/4350 0.93 (0.79-1.11) 0.73 (0.59-0.89) 
ET 215/876 1 130/4520 0.98 (0.82-1.17) 0.89 (0.72-1.10) 
MF 102/366 600/1790 0.83 (0.64-1.07) 0.60 (0.44-0.82) 
MPN-U 105/413 623/2031 0.78 (0.60-0.99) 0.52 (0.39-0.71) 
No diabetes 494/2404 2544/12 291 0.95 (0.84-1.06) 0.70 (0.63-0.82) 
No AD 581/2297 3250/11 741 0.88 (0.79-0.98) 0.69 (0.60-0.78) 

Adjusted for age, sex, and calendar time (by matching design).

Adjusted for (∗) in addition to (1) education level (primary school, high school, short/intermediate education, or long education); (2) Charlson Comorbidity Index (0, 1, or ≥2); (3) previous use of aspirin, other nonsteroidal anti-inflammatory drugs, alendronate, immunosuppressants, and metformin; and (4) previous history of alcohol-related diagnoses, overweight- and obesity-related diagnoses, chronic obstructive pulmonary disease, AD, and diabetes.